Nasdaq Stockholm AB: The observation status for Flerie AB is removed

On May 14, 2024, the shares in Flerie AB, formerly named InDex Pharmaceuticals
Holding AB (the "Company") were given observation status with reference to
plans to carry out a reverse take-over. 

On May 20, 2024, the Company issued a press release with information that the
Company had entered into a conditional agreement regarding a reverse merger
with Flerie Invest AB, conditional upon, inter alia, approval by a general
meeting of the Company's shareholders and Nasdaq Stockholm AB's decision to
admit the Company's shares for continued trading on Nasdaq First North Growth
Market. 

On June 7, 2024, the Company issued a press release with information that
Nasdaq Stockholm AB had approved the Company's shares for continued trading on
Nasdaq First North Growth Market, conditional of, inter alia, the completion of
the transaction. 

On June 10, 2024, the Company issued a press release with information that an
extraordinary general meeting of the Company's shareholders had approved the
acquisition of the shares in Flerie Invest AB. 

With reference to the above, Nasdaq Stockholm AB decides that the observation
status for the shares in Flerie AB (FLERIE, ISIN code SE0008966295, order book
ID 127479) shall be removed. 

For further information about this exchange notice please contact Enforcement &
Investigations, telephone [phone]. 


Nasdaq Stockholm AB